Original research articleBleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years1 ☆,
Introduction
The levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena) is a contraceptive method registered in Europe, Latin American, U.S., and Canada. The effectiveness was tested up to 7 years in different settings, and the cumulative pregnancy rate was from 0.0 to 0.5 up to 7 years of use [1], [2], [3].
One of the main characteristics of the LNG-IUS is to cause a reduction in the amount of blood loss during each menstrual period. Due to this characteristic, it has been used as a medical treatment for women with menorrhagia [4]. However, the reduction of blood loss is the principal cause of discontinuation among women using the device for contraception [1].
The menstrual pattern of LNG-IUS users varies depending on the population studied. However, these differences could be, in part, resulting from the women’s interpretation, the service providers’ opinion regarding bleeding pattern, or the system of evaluation. The knowledge of bleeding pattern may be helpful to counsel potential users of the device and for future clinical indications of the method.
The objectives of this study were to evaluate the bleeding patterns and clinical performance in women using LNG-IUS as a contraceptive method for up to 2 years in Campinas, Brazil.
Section snippets
Materials and methods
This was a prospective trial conducted at the Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil. The Institutional Review Board approval was obtained from the Ethical Committee of the University. All women voluntarily signed an informed consent.
A total of 256 women aged 18 to 39 years (mean 27.0 ± 0.41), who requested an IUD as a contraceptive method and accepted the LNG-IUS after explanation of
Results
Complete characterization of the cohort has been published elsewhere [3]. In summary, 60% of acceptors were in the 20 to 29 years age bracket, and more than 70% of the women had one or two previous pregnancies. The gross cumulative discontinuation rates by reason and the continuation rate are presented in Table 1. There was one pregnancy at the 15th month of use after an inadvertent expulsion of the device. The expulsion rate was significantly higher in the group that had insertion of the
Discussion
The clinical performance of the LNG-IUS was similar to the findings of other previous studies, confirming that the device is associated with high contraceptive efficacy, low risk of infection, high continuation rate, and significant reduction of menstrual bleeding [1], [2], [3], [7], [8], [9], [10], [11], [12]. The only reason for discontinuation which was significantly higher in the group with heavy menses before insertion of the device was expulsion. This finding was also observed in our
References (19)
- et al.
Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil
Contraception
(1993) - et al.
Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil
Contraception
(2000) - et al.
The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagiaa systematic review
Br J Obstet Gynaecol
(2001) - et al.
Two years’ experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine devicea randomized comparative performance study
Fertil Steril
(1983) - et al.
Ovarian function during use of a levonorgestrel-releasing IUD
Contraception
(1990) - et al.
Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system
Contraception
(1996) - et al.
Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills). An Indian experience
Contraception
(1995) - et al.
Intracervical and fundal administration of levonorgestrel for contraceptionendometrial thickness, patterns of bleeding, and persisting ovarian follicles
Fertil Steril
(1997) - et al.
Factors affecting continuation rates of DMPA
Contraception
(1999)
Cited by (206)
The levonorgestrel-releasing intrauterine device is related to early emotional reactivity: An ERP study
2024, PsychoneuroendocrinologyUse of 52-mg Levonorgestrel-Releasing Intrauterine System in Adolescents and Young Adult Women: 3-Year Follow-Up
2023, Journal of Pediatric and Adolescent GynecologyLong-acting reversible contraceptives effects in abnormal uterine bleeding, a review of the physiology and management
2022, European Journal of Obstetrics and Gynecology and Reproductive BiologyThe effect of a hysteroscopic niche resection compared with Levonorgestrel-releasing intrauterine device on postmenstrual spotting in patients with a symptomatic niche in the uterine cesarean scar: A prospective cohort study
2021, European Journal of Obstetrics and Gynecology and Reproductive Biology
- ☆
Financial support for this study was partially provided by Schering of Brasil, São Paulo, Brazil.
- 1
Mirena is a registered trademark of Leiras Oy, Turku, Finland.